Immunicon and Eisai Enter Biomarker Agreement

Immunicon Corporation (Huntington Valley, PA, USA) has entered into an agreement with Eisai, Co. Ltd. (Tokyo, Japan), for biomarker development with circulating tumor cells.

The agreement will fund biomarker development for certain proteins and their modifications associated with molecular targeted agents. Leon Terstappen, chief scientific officer of Immunicon noted, "We are pleased to work with Eisai on these important biomarkers. If successful, these proteins and their modifications will help to identify patients that may benefit from targeted therapies or to monitor treatment efficacy.”

Immunicon Corporation develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products. The company is also providing certain analytic services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count, and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells, that are important in many diseases and biologic processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular medicine and infectious diseases.

Eisai is a research-based human health care company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites, and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 9,000 people worldwide.



Related Links:
Immunicon
Eisai